

# Psychopharmacologia

## Editorial Board

D. Bovet, Sassari · J. O. Cole, Boston · J. Delay, Paris · J. Elkes, Baltimore  
 M. Hamilton, Leeds · H. Isbell, Lexington · E. Jacobsen, København  
 M. E. Jarvik, New York · S. S. Kety, Boston · C. Kornetsky, Boston · E. Rothlin, Basel  
 M. Shepherd, London · Hannah Steinberg, London · E. Strömberg, Risskov  
 A. Wikler, Lexington

## Managing Editors

J. O. Cole · M. Hamilton · E. Jacobsen · C. Kornetsky

## Advisory Board

### Neurophysiologia

F. Bremer, Bruxelles  
 J. C. Eccles, Amherst  
 A. Fessard, Paris  
 G. W. Harris, London  
 G. Moruzzi, Pisa  
 J. Z. Young, London

### Neuropharmacologia

P. B. Bradley, Birmingham  
 A. Carlsson, Göteborg  
 H. Coper, Berlin  
 E. Domino, Ann Arbor  
 D. Efron, Chevy Chase  
 U. S. von Euler, Stockholm  
 W. S. Feldberg, London  
 S. Garattini, Milano  
 L. E. Hollister, Palo Alto  
 O. Hornykiewicz, Toronto  
 E. Hosoya, Tokyo  
 S. Irwin, Portland  
 K. F. Killam, Palo Alto  
 I. P. Lapin, Leningrad  
 L. Lasagna, Baltimore  
 E. Marley, London  
 W. R. Martin, Lexington  
 H. O. Schild, London  
 F. Sjöqvist, Stockholm  
 F. Sulzer, Nashville  
 A. Weissman, Groton, Conn.  
 T. Yanagita, Kawasaki  
 E. Zaimis, London

### Neurochimia

S. Barondes, La Jolla  
 H. Blaschko, Oxford  
 J. Glowinski, Paris  
 D. Richter, Epsom  
 R. Rodnight, London  
 S. Udenfriend, Bethesda  
 H. Weil-Malherbe, Washington

### Neurologia

H. Gastaut, Marseille  
 P. van Gehuchten, Bruxelles

### Psychiatria

J. Angst, Zürich  
 H. Brill, New York  
 P. Deniker, Paris  
 P. Dick, Genève  
 F. Flügel, Erlangen  
 H. Hippus, München  
 J. Jaffe, Chicago  
 G. Klerman, Boston  
 N. S. Kline, Orangeburg  
 M. H. Lader, London  
 A. J. Lewis, London  
 O. Lingjærde, Oslo  
 P. Pichot, Paris  
 K. Rickels, Philadelphia

J. M. Rose, Leeds  
 J. Schildkraut, Boston  
 J. R. Smythies, Edinburgh  
 W. A. Stoll, Zürich  
 O. Vinar, Praha

### Psychologia

P. Carlton, New Brunswick  
 P. B. Dews, Boston  
 A. DiMascio, Boston  
 H. J. Eysenck, London  
 S. Fisher, Boston  
 S. C. Goldberg, Chevy Chase  
 S. Grossman, Chicago  
 H. Hanson, West Point  
 H. E. Hill, Lexington  
 C. R. B. Joyce, Basel  
 M. Katz, Chevy Chase  
 R. Kelleher, Boston  
 V. Laties, Rochester  
 A. Latz, Tel-Aviv  
 A. Lubin, Leeds  
 A. E. Maxwell, London  
 J. L. McGaugh, Irvine  
 A. Mirsky, Boston  
 D. Overton, Philadelphia  
 V. J. Polidora, Davis  
 R. Russell, Irvine  
 L. Stein, Philadelphia  
 A. Summerfield, London  
 T. Thompson, Minneapolis  
 O. Zangwill, Cambridge

Volume 21 · 1971



SPRINGER-VERLAG · BERLIN · HEIDELBERG · NEW YORK

J

Psychopharmacologia

With the acceptance of a manuscript for publication, the publishers acquire the sole copyright for all languages and countries, including all rights of photocopying or reproduction by any other method.

The use of registered names, trademarks etc. in this journal does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and, therefore, free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Berlag Berlin Heidelberg 1971

## Contents

	Page
Subject Index . . . . .	VI
AKKÖK, I., s. ÖZEK, M., et al. . . . .	401
AL-HACHIM, G. M.: Effect of Aldrin on the Condition Avoidance Response and Electroshock Seizure Threshold of Offspring from Aldrin-Treated Mother . . . . .	370
AMIT, Z., STERN, M. H.: A Further Investigation of Alcohol Preference in the Laboratory Rat Induced by Hypothalamic Stimulation . . . . .	317
ANDY, O. J., s. METCALF, F. U., Jr., et al. . . . .	390
APPEL, J. B.: Effects of LSD on Time-Based Schedules of Reinforcement . . . . .	174
BAYER, T., s. BHAGAT, B., et al. . . . .	287
BARKOV, N., GELLER, A., JARVIK, M. E.: The Behavioral Effects of a New Psychoactive Drug (d-Carbene) on a Passive Avoidance Response and Locomotion and Its Interaction with Amphetamine . . . . .	82
BEER, B., s. VOGEL, J. R., et al. . . . .	1
BHAGAT, B., BAYER, T., LIND, C.: Effects of Chronic Administration of Nico- tine on Drug-Induced Hypnosis in Mice . . . . .	287
BONSIGNORI, A., s. SUCHOWSKY, G. K., et al. . . . .	32
BRAND, U., s. MENGE, H. G. . . . .	212
BRIDWELL, T. J., s. HARTMANN, E., et al. . . . .	157
BROWN, H.: Some Anticholinergic-Like Behavioural Effects of Trans (-)- $\Delta^8$ Tetrahydrocannabinol . . . . .	294
BUNCE, R., s. TAYLOR, M., et al. . . . .	165
CALCUTT, C. R., DOGGETT, N. S., SPENCER, P. S. J.: Modification of the Anti- Nociceptive Activity of Morphine by Centrally Administered Ouabain and Dopamine . . . . .	111
CAPPELL, H., LEBLANC, A. E.: Some Factors Controlling Oral Morphine Intake in Rats . . . . .	192
CASTELLANO, C.: Effects of Some Anticholinergic Drugs on Water Maze Learned Behaviour in Mice . . . . .	361
CHRUŚCIEL, T. L., s. HERMAN, Z. S., et al. . . . .	66
— s. HERMAN, Z. S., et al. . . . .	74
CLODY, D. E., s. VOGEL, J. R., et al. . . . .	1
COLE, J. O., s. FINNERTY, R. J., et al. . . . .	302
COWAN, A., s. WRAY, S. R. . . . .	257
DALRYMPLE, S. D., STRETCH, R.: Effects of Amphetamine and Chlorpromazine on Second-Order Escape Behavior in Squirrel Monkeys . . . . .	268
DEMSTER, T., s. TAYLOR, M., et al. . . . .	165
DITTRICH, A.: Alteration of Behavioural Changes Induced by 3,4,5-Trimeth- oxyphenylethylamine (Mescaline) by Pretreatment with 2,4,5-Trimethoxy- phenylethylamine. A Self-Experiment . . . . .	229
DOGGETT, N. S., s. Calcutt, C. R., et al. . . . .	111
DRYBAŃSKI, A., s. HERMAN, Z. S., et al. . . . .	66
— s. HERMAN, Z. S., et al. . . . .	74
DUNLEAVY, D. L. F., MACLEAN, A. W., OSWALD, I.: Debrisoquine, Guane- thidine, Propranolol and Human Sleep . . . . .	101
ELLINGWOOD, E. H., Jr.: "Accidental Conditioning" with Chronic Meth- amphetamine Intoxication: Implications for a Theory of Drug Habituation . . . . .	131

	Page
FELDMAN, R. S., s. HOUSER, V. P. . . . .	147
FINNERTY, R. J., SOLTYS, J. J., COLE, J. O.: The Use of D-Amphetamine with Hyperkinetic Children . . . . .	302
FOX, P. A., s. MELTZER, D. . . . .	187
FRANCES, H., JACOB, J.: Comparaison des effets de substances cholinergiques et anticholinergiques sur les taux cérébraux d'acétylcholine et sur la motilité chez la souris . . . . .	338
FRÜHAUF, A., GRAUPNER, K., KÁLMÁN, E., WILDE, U.: Die Flimmer-Verschmelzungs-Frequenz unter dem Einfluß verschiedener Pharmaka . . . . .	382
GELLER, A., s. BARKOV, N., et al. . . . .	82
— ROBUSTELLI, F., JARVIK, M. E.: Cycloheximide Induced Amnesia: Its Interaction with Detention . . . . .	309
GERSHON, S., s. HO, A. K. S., et al. . . . .	238
GLICK, S. D.: Facilitation or Impairment of Learning by d-Amphetamine as a Function of Stimuli . . . . .	353
GRAUPNER, K., s. FRÜHAUF, A., et al. . . . .	382
GREENGRASS, P. M., s. TONGE, S. R. . . . .	374
GÜVENER, Z., s. ÖZEK, M., et al. . . . .	401
HARTMANN, E., BRIDWELL, T. J., SCHILDKRAUT, J. J.: Alpha-Methylparatyrosine and Sleep in the Rat . . . . .	157
HERMAN, Z. S., KMIECIAK-KOLADA, K., DRYBAŃSKI, A., SOKOŁA, A., TRZECIAK, H., CHRUSCIEL, T. L.: The Influence of 1-(o-Allylphenoxy)-3-Isopropylamine-2-Propanol Hydrochloride (Alprenolol) on the Central Nervous System of the Rat. . . . .	66
— TRZECIAK, H., CHRUSCIEL, T. L., KMIECIAK-KOLADA, K., DRYBAŃSKI, A., SOKOŁA, A.: The Influence of Prolonged Amphetamine Treatment and Amphetamine Withdrawal on Brain Biogenic Amine Content and Behaviour in the Rat . . . . .	74
HÖRTNAGL, H., s. KONZETT, H., et al. . . . .	247
HÖRTNAGL, HEIDE, s. KONZETT, H., et al. . . . .	247
HO, A. K. S., SINGER, G., GERSON, S.: Biochemical Evidence of Adrenergic Interaction with Cholinergic Function in the Central Nervous System of the Rat. 1. Effect of Norepinephrine . . . . .	238
HOUSER, V. P., FELDMAN, R. S.: The Effects of Cholinergic Agents upon Fixated Behavior . . . . .	147
JÄÄTTELÄ, A., MÄNNISTÖ, P., PAATERO, H., TUOMISTO, J.: The Effects of Diazepam or Diphenhydramine on Healthy Human Subjects . . . . .	202
JACOB, J., s. FRANCES, H. . . . .	338
JANKŮ, I., s. KRŠIAK, M. . . . .	118
JARVIK, M. E., s. BARKOV, N., et al. . . . .	82
— s. GELLER, A., et al. . . . .	309
KÁLMÁN, E., s. FRÜHAUF, A., et al. . . . .	382
KEMPEN, G. M. J. VAN: Urinary Excretion of Perphenazine and Its Sulfoxide during Administration in Oral and Long-Acting Injectable Form . . . . .	283
KIRCH, J. D., s. TANG, A. H. . . . .	139
KMIECIAK-KOLADA, K., s. HERMAN, Z. S., et al. . . . .	66
— s. HERMAN, Z. S., et al. . . . .	74
KONZETT, H., HÖRTNAGL, H., HÖRTNAGL, HEIDE, WINKLER, H.: On the Urinary Output of Vasopressin, Epinephrine and Norepinephrine during Different Stress Situations . . . . .	247
KORF, J., KUIPER, H. E.: Induction of Bizarre Behaviour in Rats by p-Chloroamphetamine, a Serotonin Depletor, after Repeated Drug Administration . . . . .	328
KRŠIAK, M., JANKŮ, I.: Measurement of Pharmacological Depression of Exploratory Activity in Mice: A Contribution to the Problem of Time-Economy and Sensitivity . . . . .	118
KUIPER, H. E., s. KORF, J. . . . .	328

# Contents

V

Page

LARSSON, K., SÖDERSTEN, P.: Lordosis Behavior in Male Rats Treated with Estrogen in Combination with Tetrabenazine and Nialamide . . . . .	13
LEBLANC, A. E., s. CAPPELL, H. . . . .	192
LEWANDER, T.: A Mechanism for the Development of Tolerance to Amphetamine in Rats . . . . .	17
LIND, C., s. BHAGAT, B., et al. . . . .	287
LIVESEY, J., s. TAYLOR, M., et al. . . . .	165
MÄNNISTÖ, P., s. JÄÄTTELÄ, A., et al. . . . .	202
MACLEAN, A. W., s. DUNLEAVY, D. L. F., et al. . . . .	101
MELTZER, D., FOX, P. A.: Increases in Spontaneous Activity Following Intermittent Imipramine Administration . . . . .	187
MENGE, H. G., BRAND, U.: Untersuchungen über die Stereotypien nach Amphetamin und Apomorphin sowie deren pharmakologische Beeinflussung .	212
METCALF, F. U., Jr., PEELER, D. F., Jr., ANDY, O. J.: Methamphetamine Effects upon Avoidance Behavior during Limbic Seizures in the Cat. . .	390
MORTILLARO, M.: Der Einfluß von Harmin auf die bioelektrische Aktivität des Hippocampus der Ratte . . . . .	49
ÖZEK, M., TÖRECI, K., AKKÖK, I., GÜVENER, Z.: Die Wirkung der Neuroleptica-Behandlung auf die Antikörperbildung . . . . .	401
OSWALD, I., s. DUNLEAVY, D. L. F., et al. . . . .	101
PAATERO, H., s. JÄÄTTELÄ, A., et al. . . . .	202
PARDO, E. G., s. RODRÍGUEZ, R. . . . .	89
PEELER, D. F., Jr., s. METCALF, F. U., Jr., et al. . . . .	390
PEGRASSI, L., s. SUCHOWSKY, G. K., et al. . . . .	32
PRINCIPI, K., s. VOGEL, J. R. . . . .	8
RÍO, J. DEL: Facilitating Effects of Some Chlorpromazine-D-Amphetamine Mixtures on Avoidance Learning . . . . .	39
ROBUSTELLI, F., s. GELLER, A., et al. . . . .	309
RODRÍGUEZ, R., PARDO, E. G.: Quipazine, a New Type of Antidepressant Agent . . . . .	89
SCHILDKRAUT, J. J., s. HARTMANN, E., et al. . . . .	157
SINGER, G., s. HO, A. K. S., et al. . . . .	238
SÖDERSTEN, P., s. LAESSON, K. . . . .	13
SOLTYS, J. J., s. FINNERTY, R. J., et al. . . . .	302
SOKOLA, A., s. HERMAN, Z. S., et al. . . . .	66
— s. HERMAN, Z. S., et al. . . . .	74
SPENCER, P. S. J., s. CALCUTT, C. R., et al. . . . .	111
STERN, M. H., s. AMIT, Z. . . . .	317
STRETCH, R., s. DALRYMPLE, S. D. . . . .	268
SUCHOWSKY, G. K., PEGRASSI, L., BONSIGNORI, A.: Steroids and Aggressive Behaviour in Isolated Male and Female Mice . . . . .	32
TANG, A. H., KIRCH, J. D.: Appetite Suppression and Central Nervous System Stimulation in the Rhesus Monkey . . . . .	139
TAYLOR, M., LIVESEY, J., DEMPSTER, T., BUNCE, R.: The Effects of Acutely Administered Fenfluramine on Activity and Eating Behaviour . . . . .	165
TÖRECI, K., s. ÖZEK, M., et al. . . . .	401
TONGE, S. R., GREENGRASS, P. M.: The Acute Effects of Oestrogen and Progesterone on the Monoamine Levels of the Brain of Ovariectomised Rats .	374
TRZECIAK, H., s. HERMAN, Z. S., et al. . . . .	66
— s. HERMAN, Z. S., et al. . . . .	74
TUOMISTO, J., s. JÄÄTTELÄ, A., et al. . . . .	202
VOGEL, J. R., BEER, B., CLODY, D. E.: A Simple and Reliable Conflict Procedure for Testing Anti-Anxiety Agents . . . . .	1
— PRINCIPI, K.: Effects of Chlordiazepoxide on Depressed Performance after Reward Reduction . . . . .	8

	Page
WEISSMAN, A.: Cliff Jumping in Rats after Intravenous Treatment with Apomorphine	60
WILDE, U., s. FRÜHAUF, A., et al.	382
WINKLER, H., s. KONZETT, H., et al.	247
WRAY, S. R., COWAN, A.: The Behavioural Effects of Levallorphan, Cyprenorphine (M 285) and Amphetamine on Repeated Y-Maze Performance in Rats	257

Indexed in Current Contents

## Subject Index

### A

acetylcholine 238, 338  
 activity 165, 187, 257  
 adrenergic interaction 238  
 aggressive behavior 32  
 alcohol 317  
 aldrin 370  
 alperenolol 66  
 alpha-methylparatyrosine 157  
 amines, brain 66, 74, 374  
 amnesia, induced 309  
 amphetamine 1, 17, 39, 66, 74, 82, 101, 131, 212, 257, 268, 294, 302, 328, 338, 353  
 amphetamine withdrawal 74  
 anorexia 17, 165  
 antagonism 82, 229, 268, 294  
 antibody formation 401  
 anticholinergic 294, 338, 361  
 antidepressants 89  
 anti-nociception 111  
 anxiety, anti- 1  
 apomorphine 60, 212  
 appetite suppressants 139  
 arecholine 338  
 atropine 361  
 avoidance 82, 390  
 avoidance learning 39, 268, 309, 370

### B

barbitone 118  
 $\beta$ -blockers 101  
 behaviour 66, 74, 302  
 behavioural depression 8  
 behaviour, bizarre 328  
 behaviour, oestrous 374  
 benactyzine 361  
 benzodiazepines 1  
 bioelectrical activity 49  
 brain amines 66, 74, 374

### C

cafein 382  
 carbidin 82  
 castration 13, 32  
 catecholamines 157  
 cats 89, 131, 390  
 children 382  
 children, hyperkinetic 302  
 chlordiazepoxide 1, 8  
 chloroamphetamine, p- 328  
 chlorphentermine 131  
 chlorpromazine 39, 82, 118, 268, 294  
 choline acetylase activity 238  
 cholinergic function 238, 294, 338  
 cliff-jumping 60  
 cold application 247  
 conflict 1  
 cycloheximide 309  
 cyprenorphine 257

### D

D-amphetamine sulfate 1, 39  
 DDT 370  
 debrisoquine 101  
 desmethylimipramine 60  
 desynchronized sleep 157  
 detention 309  
 dexamphetamine 101  
 dextroamphetamine 302  
 diastolic blood pressure 247  
 diazepam 1, 202  
 dieldrin 370  
 diphenhydramine 202  
 ditran 361  
 dopamine 60, 66, 111, 238  
 drug-abuse 131  
 drug-induced hypnosis 287  
 drug tolerance 17, 238



**E**

eating behaviour 165, 238  
epinephrine 247  
escape behaviour, second order 268  
eserine 338  
estrogen 13, 32, 374  
ethanol 287  
exploration 118

**F**

fast activity in HC 49  
fenfluramine 131, 165  
fixated behaviour 147  
flicker fusion 382

**G**

glycolate 294  
guanethidine 101

**H**

habituation 257  
hallucinogens 294  
harmin 49  
heart rate 247  
hippocampus, rat 49  
humans 101, 202, 247, 283, 302, 382, 401  
5-hydroxytryptamine 66, 74, 328  
hyperkinetic children 302  
hyperthermia 17  
hypnosis, drug-induced 281  
hypothalamus 317

**I**

imipramine 82, 101, 187  
immunoglobulins 401  
impairment 82  
inhibition 8  
intellectual performance 302  
intraventricular 238  
isolation 32  
isoprenaline 101

**L**

Lashley jumping stand 147  
learning 353  
levallorphan 257  
limbic seizures 390  
lordosis 13  
lysergic acid diethylamide (LSD) 174

**M**

magnesium pemoline 1  
male rat 13  
MAOI 101  
MAO inhibitor 49  
memory 309  
meprobamate 1, 382  
mescaline 229  
methadrine 131  
methamphetamine 131, 390

mice 32, 82, 89, 111, 118, 212, 287, 294,  
309, 338, 361, 370  
monkeys, rhesus 131  
monkeys, squirrel 268  
monoamines 238, 374  
morphine 111, 192  
motor activity 338

**N**

narcotic antagonist 257  
neuroleptics 212, 401  
nialamide 13  
nicotine 287  
noradrenaline 66, 74, 101  
norepinephrine 157, 238, 247

**O**

oestrogen 13, 32, 374  
operant behaviour 39  
oral self-administration 192  
ouabain 111  
ovariectomised rats 374  
oxazepam 1

**P**

pain production 247  
passive avoidance 309  
p-chloramphetamine 328  
pentobarbitol 1  
performance test 247  
perphenazine 283  
perphenazine enanthate 283  
pilocarpine 147  
phenethylamine 131  
p-hydroxyamphetamine 17  
p-hydroxynorephedrine 17  
potentiation 229  
preference 317  
premedication 192  
progesterone 374  
propranolol 101  
psychotomimetic 257  
punishment 174

**Q**

quipazine 89

**R**

rats 1, 8, 13, 17, 39, 49, 60, 66, 74, 89,  
147, 157, 165, 174, 187, 192, 212, 238,  
257, 317, 328, 353, 374  
regulation 192  
relationship (amphetamine carbidin) 82  
reversal 317  
reward reduction 8

**S**

schizophrenics 401  
scopolamine 1, 147, 361

# VIII

# Subject Index

septal after discharge 390  
 septal stimulation 390  
 serotonin 89, 238, 328  
 seizure threshold 370  
 sleep 101, 157  
 spayed female mice 32  
 stereotypy 212  
 steroids 32  
 stimulation, hypothalamic 317  
 stress 247, 257  
 sympathomimetics 17  
 synergism 82  
 systolic blood pressure 247

## T

tacrine 294  
 test-sensitivity 118  
 tetrabenazine 13  
 tetrahydrocannabinols 294

theta-rhythm 49  
 thymoleptics 212  
 time-economy 118  
 time sampling technique 165  
 timing behaviour 174  
 tolerance, drug 17  
 tranquilizers, minor 1  
 2,4,5-trimethoxyphenylethylamine 229

## U

urinary excretion 17, 283  
 urine volume 247

## V

variable interval (VI) 174  
 vasopressin 247

## Y

Y-maze 257



## Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawing etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wide margin on the left. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:

- a) the title;
- b) the name(s) of the author(s);
- c) the name of the laboratory where the work was carried out;
- d) a running title of not more than 67 typewriter strokes;
- e) footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**

French and German articles should also have an English translation of the title.

7. Immediately following the **abstract**, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the title or authors of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. *Psychopharmacologia (Berl.)* 14, 23—32 (1969).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. *In: Neuropsychopharmacology*. P. B.

Bradley, F. Flugle and P. Hoch, eds., vol. 3, pp. 149—156. Amsterdam: Elsevier 1964. Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Bindra and Mendelson, 1963) or (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Mann (1966) reported that..." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first author, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. It must be emphasized that a maximum area available is 108 × 177 mm ( $4\frac{1}{4} \times 7''$ ). Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the blockmaker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).



**SPRINGER-VERLAG**  
BERLIN · HEIDELBERG · NEW YORK

## **Das AMP-System**

**Manual zur Dokumentation psychiatrischer Befunde**

Herausgegeben von der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMP). Zusammengestellt und redigiert von  
Dr. med. **Christian Scharfetter**, Universität Zürich  
Stand: Januar 1971

88 Seiten. 1971  
Geheftet DM 3,50  
US \$ 1.10

Definitionen und Kommentare zu den von der Internationalen Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie entwickelten Befunddokumentationsblättern, die als Grundlage elektronischer Datenverarbeitung der internationalen Vereinheitlichung psychiatrischer Diagnostik und Forschung dienen.

## **Diagnosenschlüssel und Glossar psychiatrischer Krankheiten**

Deutsche Übersetzung der internationalen Klassifikation der WHO: ICD  
(ICD = International Classification of Diseases), 8. Revision, und  
des internationalen Glossars

Herausgeber: Arbeitsgruppe der WHO für das internationale Glossar und  
Kommission für Klassifikation und Diagnosenschema der Deutschen  
Gesellschaft für Psychiatrie und Nervenheilkunde (DGPN),  
Vorsitzender: H. Helmchen. Übersetzung: W. Mombour und G. Kockott  
Stand: Sommer 1971

2., korrigierte Auflage  
VIII, 67 Seiten. 1971  
Geheftet DM 6,—  
US \$ 1.80

Die international einheitlich geregelte Verwendung  
psychiatrisch-diagnostischer Begriffe führt zu einer  
klarerer Verständigung der Psychiater untereinander  
und schafft die Voraussetzung für eine Epidemiologie  
psychischer Krankheiten.



